Advertisement

Tumor Biology

, Volume 35, Issue 12, pp 12131–12137 | Cite as

Increased expression of Chitinase 3-like 1 and microvessel density predicts metastasis and poor prognosis in clear cell renal cell carcinoma

  • Jian-Ping Zhang
  • Hai-Xia Yuan
  • Wen-Tao Kong
  • Yujun Liu
  • Zong-Ming Lin
  • Wen-Ping Wangs
  • Jian-Ming Guo
Research Article

Abstract

Increasing evidence demonstrated that Chitinase 3-like 1 (hereafter termed CHI3L1 or YKL-40) was highly expressed and tightly associated with human tumor development and progression. However, its precise role in clear cell renal cell carcinoma (hereafter termed RCC) remains to be delineated. In the present study, we investigated the relationship between CHI3L1 expression and microvessel density (MVD), a reflection of angiogenesis, with metastasis and prognosis in patients with clear cell renal cell carcinoma (RCC). Formalin-fixed, paraffin-embedded tissue sections of clear cell RCC from 73 patients who had undergone radical nephrectomy were stained immunohistochemically with specific antibodies against CHI3L1 and CD34. CHI3L1 immunostaining was semi-quantitatively estimated based on the proportion (percentage of positive cells) and intensity. MVD was determined with CD34-stained slides. The expression pattern of CHI3L1 and MVD was compared with the clinicopathological variables. Twenty patients had either synchronous or metachronous metastases and 12 died during the follow-up. CHI3L1 intensity was significantly correlated with tumor size (P = 0.005), TNM stage (P = 0.027), M stage (P = 0.011), grade (P = 0.014), and metastasis (synchronous or metachronous; P < 0.001). The CHI3L1 proportion (P = 0.038) and MVD (P = 0.012) were significantly correlated with metastasis. MVD was correlated with CHI3L1 intensity (r = 0.376, P = 0.001) and CHI3L1 proportion (r = 0.364, P = 0.002). There was no difference in the expression of CHI3L1 and MVD between primary and metastatic sites. The survival of patients with higher CHI3L1 intensity was significantly worse than that of patients with lower CHI3L1 intensity. Multivariate analyses indicated that only M stage was an independent prognostic factor for cancer-specific survival and CHI3L1 expression was not an independent factor. Taken altogether, increased expression of CHI3L1 and MVD is associated with metastasis and a worse prognosis in clear cell RCC. CHI3L1 expression is correlated with MVD. The results suggest that CHI3L1 may be important in the progression and angiogenesis of clear cell RCC and CHI3L1 might be a novel strategy for therapy of the patients with RCC.

Keywords

CHI3L1 Microvessel density Metastasis Prognosis Renal cell carcinoma 

Notes

Acknowledgments

Special thanks to the faculty of Department of Pathology, Zhongshan Hospital, Fudan University.

Conflicts of interest

None.

References

  1. 1.
    Miyamoto H, Miller JS, Fajardo DA, Lee TK, Netto GJ, Epstein JI, et al. Non-invasive papillary urothelial neoplasms: the 2004 WHO/ISUP classification system. Pathol Int. 2010;60:1–8.PubMedCrossRefGoogle Scholar
  2. 2.
    Montironi R, Santinelli A, Pomante R, Mazzucchelli R, Colanzi P, Filho AL. Morphometric index of adult renal cell carcinoma. Comparison with the Fuhrman grading system. Virchows Arch. 2000;437(1):82–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Matsuura K, Nakada C, Mashio M, Narimatsu T, Yoshimoto T, Tanigawa M, et al. Downregulation of SAV1 plays a role in pathogenesis of high-grade clear cell renal cell carcinoma. BMC Cancer. 2011;11:523.PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Yaycioglu O, Eskicorapci S, Karabulut E, Soyupak B, Gogus C, Divrik T, et al. A preoperative prognostic model predicting recurrence-free survival for patients with kidney cancer. Jpn J Clin Oncol. 2013;43(1):63–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Hakala BE, White C, Recklies AD. Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells, is a mammalian member of a chitinase protein family. J Biol Chem. 1993;268(34):25803–10.PubMedGoogle Scholar
  6. 6.
    Zivanović S, Rackov LP, Vojvodić D, Vucetić D. Human cartilage glycoprotein 39—biomarker of joint damage in knee osteoarthritis. Int Orthop. 2009;33(4):1165–70.PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Lee IA, Kamba A, Low D, Mizoguchi E. Novel methylxanthine derivative-mediated anti-inflammatory effects in inflammatory bowel disease. World J Gastroenterol. 2014;20(5):1127–38.PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Johansen JS, Milman N, Hansen M, Garbarsch C, Price PA, Graudal N. Increased serum YKL-40 in patients with pulmonary sarcoidosis—a potential marker of disease activity? Respir Med. 2005;99(4):396–402.PubMedCrossRefGoogle Scholar
  9. 9.
    Nordenbaek C, Johansen JS, Halberg P, Wiik A, Garbarsch C, Ullman S, et al. High serum levels of YKL-40 in patients with systemic sclerosis are associated with pulmonary involvement. Scand J Rheumatol. 2005;34(4):293–7.PubMedCrossRefGoogle Scholar
  10. 10.
    Schiavon LL, Carvalho-Filho RJ, Narciso-Schiavon JL, Medina-Pestana JO, Lanzoni VP, Ferraz ML, et al. YKL-40 and hyaluronic acid (HA) as noninvasive markers of liver fibrosis in kidney transplant patients with HCV chronic infection. Scand J Gastroenterol. 2010;45(5):615–22.PubMedCrossRefGoogle Scholar
  11. 11.
    Mitsuhashi A, Matsui H, Usui H, Nagai Y, Tate S, Unno Y, et al. Serum YKL-40 as a marker for cervical adenocarcinoma. Ann Oncol. 2009;20(1):71–7.PubMedCrossRefGoogle Scholar
  12. 12.
    Shao R, Cao QJ, Arenas RB, Bigelow C, Bentley B, Yan W. Breast cancer expression of YKL-40 correlates with tumour grade, poor differentiation, and other cancer markers. Br J Cancer. 2011;105(8):1203–9.PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Sharma SG, Aggarwal N, Gupta SD, Singh MK, Gupta R, Dinda AK. Angiogenesis in renal cell carcinoma: correlation of microvessel density and microvessel area with other prognostic factors. Int Urol Nephrol. 2011;43(1):125–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Yoshino S, Kato M, Okada K. Clinical significance of angiogenesis, proliferation and apoptosis in renal cell carcinoma. Anticancer Res. 2000;20(1C):591–4.PubMedGoogle Scholar
  15. 15.
    Zhang B, Ji H, Yan D, Liu S, Shi B. Lack of association of microvessel density with prognosis of renal cell carcinoma: evidence from meta-analysis. Tumour Biol. 2014;35(3):2769–76.PubMedCrossRefGoogle Scholar
  16. 16.
    Hemmerlein B, Galuschka L, Putzer N, Zischkau S, Heuser M. Comparative analysis of COX-2, vascular endothelial growth factor and microvessel density in human renal cell carcinomas. Histopathology. 2004;45(6):603–11.PubMedCrossRefGoogle Scholar
  17. 17.
    Cao Y, Zhang ZL, Zhou M, Elson P, Rini B, Aydin H, et al. Pericyte coverage of differentiated vessels inside tumor vasculature is an independent unfavorable prognostic factor for patients with clear cell renal cell carcinoma. Cancer. 2013;119(2):313–24.PubMedCrossRefGoogle Scholar
  18. 18.
    Ficarra V, Galfano A, Mancini M, Martignoni G, Artibani W. TNM staging system for renal-cell carcinoma: current status and future perspectives. Lancet Oncol. 2007;8(6):554–8.PubMedCrossRefGoogle Scholar
  19. 19.
    Kirkali Z, Algaba F, Scarpelli M, Trias I, Selvaggi FP, Van Poppel H. What does the urologist expect from the pathologist (and what can the pathologists give) in reporting on adult kidney tumour specimens? Eur Urol. 2007;51(5):1194–201.PubMedCrossRefGoogle Scholar
  20. 20.
    Vartanian RK, Weidner N. Endothelial cell proliferation in prostatic carcinoma and prostatic hyperplasia: correlation with Gleason's score, microvessel density, and epithelial cell proliferation. Lab Investig. 1995;73(6):844–50.PubMedGoogle Scholar
  21. 21.
    Recklies AD, White C, Ling H. The chitinase 3-like protein human cartilage glycoprotein 39 (HC-gp39) stimulates proliferation of human connective-tissue cells and activates both extracellular signal-regulated kinase- and protein kinase B-mediated signalling pathways. Biochem J. 2002;365(Pt 1):119–26.PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    Kim MN, Lee KE, Hong JY, Heo WI, Kim KW, Kim KE, et al. Involvement of the MAPK and PI3K pathways in chitinase 3-like 1-regulated hyperoxia-induced airway epithelial cell death. Biochem Biophys Res Commun. 2012;421(4):790–6.PubMedCrossRefGoogle Scholar
  23. 23.
    Harving ML, Christensen LH, Ringsholt M, Lausten GS, Petersen MM. YKL-40 expression in soft-tissue sarcomas and atypical lipomatous tumors. An immunohistochemical study of 49 tumors. Acta Orthop. 2014;85(2):195–200.PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Libreros S, Garcia-Areas R, Keating P, Carrio R, Iragavarapu-Charyulu VL. Exploring the role of CHI3L1 in “pre-metastatic” lungs of mammary tumor-bearing mice. Front Physiol. 2013;4:392.PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    Özdemir E, Çiçek T, Kaya MO. Association of serum YKL-40 level with tumor burden and metastatic stage of prostate cancer. Urol J. 2012;9(3):568–73.PubMedGoogle Scholar
  26. 26.
    Castellano I, Mistrangelo M, Crudo V, Chiusa L, Lupo R, Ricardi U, et al. YKL-40 expression in anal carcinoma predicts shorter overall and disease-free survival. Histopathology. 2009;55(2):238–40.PubMedCrossRefGoogle Scholar
  27. 27.
    Antonelli M, Massimino M, Morra I, Garrè ML, Gardiman MP, Buttarelli FR, et al. Expression of pERK and pAKT in pediatric high grade astrocytomas: correlation with YKL40 and prognostic significance. Neuropathology. 2012;32(2):133–8.PubMedCrossRefGoogle Scholar
  28. 28.
    Ngernyuang N, Francescone RA, Jearanaikoon P, Daduang J, Supoken A, Yan W, et al. Chitinase 3 like 1 is associated with tumor angiogenesis in cervical cancer. Int J Biochem Cell Biol. 2014;51:45–52.PubMedCrossRefGoogle Scholar
  29. 29.
    Francescone RA, Scully S, Faibish M, Taylor SL, Oh D, Moral L, et al. Role of YKL-40 in the angiogenesis, radioresistance, and progression of glioblastoma. J Biol Chem. 2011;286(17):15332–43.PubMedCentralPubMedCrossRefGoogle Scholar
  30. 30.
    Rathcke CN, Vestergaard H. YKL-40, a new inflammatory marker with relation to insulin resistance and with a role in endothelial dysfunction and atherosclerosis. Inflamm Res. 2006;55(6):221–7.PubMedCrossRefGoogle Scholar
  31. 31.
    Tang H, Sun Y, Shi Z, Huang H, Fang Z, Chen J, et al. YKL-40 induces IL-8 expression from bronchial epithelium via MAPK (JNK and ERK) and NF-κB pathways, causing bronchial smooth muscle proliferation and migration. J Immunol. 2013;190(1):438–46.PubMedCrossRefGoogle Scholar
  32. 32.
    Görgens SW, Eckardt K, Elsen M, Tennagels N, Eckel J. Chitinase-3-like protein 1 protects skeletal muscle from TNFα-induced inflammation and insulin resistance. Biochem J. 2014;459(3):479–88.PubMedCrossRefGoogle Scholar
  33. 33.
    He CH, Lee CG, Dela Cruz CS, Lee CM, Zhou Y, Ahangari F. Chitinase 3-like 1 regulates cellular and tissue responses via IL-13 receptor α2. Cell Rep. 2013;4(4):830–41.PubMedCentralPubMedCrossRefGoogle Scholar
  34. 34.
    Francescone R, Ngernyuang N, Yan W, Bentley B, Shao R. Tumor-derived mural-like cells coordinate with endothelial cells: role of YKL-40 in mural cell-mediated angiogenesis. Oncogene. 2014;33(16):2110–22.PubMedCentralPubMedCrossRefGoogle Scholar
  35. 35.
    Joly F. Renal carcinoma and fatigue: which challenge in the era of antiangiogenic drugs? Bull Cancer. 2011;98(9):1071–81.PubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Jian-Ping Zhang
    • 1
  • Hai-Xia Yuan
    • 2
  • Wen-Tao Kong
    • 1
  • Yujun Liu
    • 1
  • Zong-Ming Lin
    • 1
  • Wen-Ping Wangs
    • 2
  • Jian-Ming Guo
    • 1
  1. 1.Department of Urology, Zhongshan HospitalFudan UniversityShanghaiPeople’s Republic of China
  2. 2.Department of Ultrasound, Zhongshan HospitalFudan UniversityShanghaiPeople’s Republic of China

Personalised recommendations